VYNE Therapeutics Inc. Annual Income Tax Expense (Benefit) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
VYNE Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2017 to 2023.
  • VYNE Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000.
  • VYNE Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $0.000, a 100% decline year-over-year.
  • VYNE Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000, a 100% decline from 2022.
  • VYNE Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $13K.
  • VYNE Therapeutics Inc. annual Income Tax Expense (Benefit) for 2021 was -$448K, a 73.6% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $0 -$13K -100% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-01
2022 $13K +$461K Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 -$448K -$190K -73.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 -$258K -$82K -46.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$176K -$388K -183% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-04
2018 $212K +$212K Jan 1, 2018 Dec 31, 2018 10-K 2021-03-04
2017 $0 Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.